**Question:** Which of the following statements is not true regarding hemolytic uremic syndrome?

A. Hemolytic uremic syndrome is a rare complication of severe infections like Escherichia coli (E. coli) O157:H7.
B. Hemolytic uremic syndrome is a rare complication of using certain medications like antibiotics or immunosuppressants.
C. Hemolytic uremic syndrome is a rare complication of thrombotic thrombocytopenic purpura (TTP).
D. Hemolytic uremic syndrome is a rare complication of sickle cell anemia.

**Correct Answer:**

**Option D:** Hemolytic uremic syndrome is a rare complication of sickle cell anemia.

**Why the Correct Answer is Right:**

Hemolytic uremic syndrome (HUS) is primarily associated with infections, particularly due to Shiga toxin-producing Escherichia coli (E. coli) like O157:H7. It is not directly linked to sickle cell anemia. In sickle cell anemia, the primary issue is with the abnormal hemoglobin structure leading to hemolysis and red blood cell (RBC) destruction. This results in microangiopathic hemolytic anemia, rather than the thrombotic microangiopathy seen in HUS.

**Why Each Wrong Option is Incorrect:**

**Option A:** This statement is correct, as E. coli O157:H7 is one of the primary causative agents of HUS.

**Option B:** While some medications can cause a similar condition, thrombotic microangiopathy, it is not specific to HUS. This statement is incorrect as not all medications result in HUS and not all HUS cases are medication-induced.

**Option C:** HUS is a distinct entity from thrombotic thrombocytopenic purpura (TTP). They share some features but have different underlying mechanisms. TTP is caused by a deficiency in ADAMTS13 enzyme, leading to uncontrolled platelet aggregation and microangiopathic hemolytic anemia. HUS, however, is primarily caused by infections, toxins, or genetic defects in the complement system (e.g., mutations in CFH, C3, or MCP genes).

**Option D:** HUS is not directly associated with sickle cell anemia, which is a separate disorder characterized by hemolysis, vaso-occlusive crises, and complications like stroke, pulmonary hypertension, and avascular necrosis.

**Clinical Pearls:**

Hemolytic uremic syndrome is a serious complication that can occur in sickle cell anemia, but it is not the primary cause or consequence of the disease. Instead, complications such as stroke, pulmonary hypertension, and avascular necrosis are more commonly associated with sickle cell anemia. Understanding the correct relationship between sickle cell anemia, HUS, and the other options provided is crucial for identifying and managing these conditions effectively in clinical practice.